2012
Poly (ADP-ribose) polymerase inhibitors
Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) polymerase inhibitors. Current Opinion In Oncology 2012, 24: 564-571. PMID: 22759740, PMCID: PMC3799945, DOI: 10.1097/cco.0b013e3283564230.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerOverall survivalEOC patientsPARP inhibitorsBRCA mutationsHereditary epithelial ovarian cancerLower chemotherapy response rateDNA repair defectsDeleterious BRCA1/2 mutationsPlatinum-based chemotherapyRecurrence-free survivalChemotherapy response rateRecent clinical trialsPoor overall survivalNew treatment optionsShorter survival timeSporadic epithelial ovarian cancerPoly (ADP-ribose) polymerasePoly (ADP-ribose) polymerase (PARP) inhibitorsEffect of cisplatinPARP inhibitor olaparibRecurrent diseaseClinical outcomesTherapeutic challenge
2011
Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer Mature Results of the Phase 2 PBM-PFU Protocol
McCaffrey R, Bahtiyar M, Kohorn EI, Chambers JT, Schwartz PE, Chambers SK. Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer Mature Results of the Phase 2 PBM-PFU Protocol. International Journal Of Gynecological Cancer 2011, 21: 535-544. PMID: 21436702, DOI: 10.1097/igc.0b013e31820c4c8d.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinCarcinoma, AdenosquamousCarcinoma, Squamous CellChemotherapy, AdjuvantCisplatinFemaleFluorouracilHumansLeucovorinMaximum Tolerated DoseMethotrexateMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingProspective StudiesSurvival RateTreatment OutcomeUterine Cervical NeoplasmsYoung AdultConceptsLymph nodesRadiation therapyResponse rateSurvival ratePathologic complete response rateCisplatin-based neoadjuvant chemotherapyAdjuvant chemotherapy armComplete response rateConsolidation radiation therapyStage IIB cancerDisease-free survivalHigh-risk featuresPercent of patientsPositive lymph nodesPostoperative radiation therapyChemotherapy response rateAdjuvant casesAdjuvant chemotherapyChemotherapy armChemotherapy eraNeoadjuvant groupNonsquamous histologyNeoadjuvant chemotherapyAdjuvant groupOverall survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply